CareDx Inc

CDNA remains in a Stage 2 advance within an intact long-term uptrend; despite an extreme overbought peak, no active reversal patterns are present and medium-term bias stays bullish. However, price is still extended above the rising EMAs, so immediate entries are less favorable. We will stalk for a clear pullback into the 9- and 21-day EMA support zone before buying. Key risks include a failed pullback that turns into a deeper correction or a prolonged extension that delays entry.

• ↑Q1 2026 revenue of $118 M (+39% YoY); testing services revenue $91 M (+48% YoY).
• ↑Adjusted EBITDA $19 M (+300% YoY) driven by record cash realizations from RCM.
• ↓Potential $15 M headwind from proposed LCD reimbursement cuts.